Stockreport

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

Silence Therapeutics Plc - American Depository Share  (SLN) 
PDF Rapid Completion of Phase 2 Enrollment Reflects Ongoing Momentum for Divesiran as First-in-Class siRNA for PVTopline Results Anticipated in 3Q’26 LONDON--(BUSINESS WI [Read more]